成纤维细胞激活蛋白靶向PET/CT显像在PSMA低表达初治前列腺癌患者中的应用
本病例报告描述一名76岁新诊断前列腺癌患者,18F-PSMA-1007 PET/CT显示原发肿瘤及转移灶PSMA活性极低,而18F-FAPI-04 PET/CT在原发肿瘤、转移淋巴结及骨病灶中显示更多高摄取病灶,后续组织病理学检查证实前列腺癌诊断。作者认为18F-FAPI-04可能对评估PSMA低表达的初治前列腺癌患者具有潜在作用。
要点
- 76岁新诊断前列腺癌患者18F-PSMA-1007 PET/CT原发灶及转移灶PSMA活性极低。
- 18F-FAPI-04 PET/CT在原发肿瘤、转移淋巴结及骨病灶中显示更多高摄取病灶。
- 作者认为18F-FAPI-04可能对PSMA低表达初治前列腺癌的评估具有潜在作用。
核心结论
- 作者认为18F-FAPI-04可能对评估PSMA低表达的初治前列腺癌患者具有潜在作用。
研究设计与样本
- 病例报告,对象为一名76岁新诊断前列腺癌患者。
主要发现
- 18F-PSMA-1007 PET/CT显示原发肿瘤及转移灶PSMA活性极低。
- 18F-FAPI-04 PET/CT在原发肿瘤、转移淋巴结及骨病灶中显示更多高摄取病灶。
- 后续组织病理学检查证实前列腺癌诊断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) PET/CT has become increasingly accepted for imaging prostate cancer (PCa), including its recent use in primary staging. In this case report, we present the case of a 76-year-old man with newly diagnosed PCa. 18 F-PSMA-1007 PET/CT showed minimal PSMA activity in the primary tumor and metastases. However, 18 F-FAPI-04 PET/CT revealed more avid lesions in primary tumor, metastatic lymph nodes, and bones. Subsequent histopathologic examination confirmed the diagnosis of PCa. These findings suggest that 18 F-FAPI-04 may have a potential role in the evaluation of PCa with low PSMA expression in treatment-naive patients.
引用
- Mu X, Li M, Huang J, et al. Fibroblast Activation Protein-Targeted PET/CT Imaging in a Treatment-Naive Prostate Cancer Patient With Low PSMA Expression. Clin Nucl Med. 2023. PMID: 37703425. doi:10.1097/RLU.0000000000004825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。